CD47 and diffuse large B-cell lymphoma: These findings indicate that inhibition of the CD47-SIRPα antiphagocytic axis and activation of prophagocytic signaling with rituximab have an enhanced antitumor effect in DLBCL cell lines compared with rituximab alone.